Five-Year Survival Data for Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KEYNOTE Trial at 2019 ASCO Annual Meeting

These five-year data provide important insights into the long-term safety and efficacy of KEYTRUDA in patients with advanced non-small cell lung cancer.